Abstract
Objective This study aimed to analyze the effect of hydroxychloroquine combined with Huangqi tablets in the treatment of diabetic nephropathy (DN). Methods Eighty patients with DN were enrolled and divided into two groups by a random number table. 27 patients received routine treatment + hydroxychloroquine (group A), while 27 patients received routine treatment + hydroxychloroquine + Huangqi tablets (group B) and 26 patients received routine treatment (group C). Results FPG, 2h PG, and HbA1c levels as well as TC and TG levels were lower in group B than in groups A and C at the end of 3 months of treatment and were lower in group A than in group C (P < 0.05). SCR, BUN, and 24-hour urine protein were reduced in group B after therapy, whereas eGFR was increased and the difference between groups A and C was significant (P=0.05). After treatment, VEGF, IGF-1, and TGF-1 levels were lower in group B than in groups A and C and in group A than in group C (P=0.05). Total symptom scores at 2, 4, and 6 months after treatment was lower in group B than in groups A and C, and they were lower in group A than in group C at all time points (P < 0.05). The total effective rates of treatment in groups A, B, and C were 66.67%, 88.89%, and 38.46% (P < 0.05). The incidence of adverse reactions in groups A, B, and C was 37.04%, 25.93%, and 11.54% (P > 0.05). Conclusion Hydroxychloroquine combined with Huangqi tablets in the treatment of DN showed the best efficacy, with better control of blood glucose and lipids, which can more effectively delay the progression of renal lesions and effectively inhibit the expression of VEGF, IGF, and TGF-β1 in tethered cells with high safety.
Highlights
Diabetic nephropathy (DN) is a common complication of type 2 diabetes
Baseline Data. ere was no statistical difference in gender, mean age, mean body mass index (BMI), duration of type 2 diabetes, and duration of DN among groups A, B, and C (P > 0.05) (Table 1)
Modern research has shown that the occurrence of DN correlated with combined factors such as genetics, hypertension, hyperglycemia, biochemical metabolic disorders, abnormal blood rheology, and abnormal expression of cytokines [13, 16]
Summary
Diabetic nephropathy (DN) is a common complication of type 2 diabetes. If left untreated, it can lead to glomerulosclerosis, which can seriously increase the disability and mortality rates in patients with type 2 diabetes [1]. DN is considered to contribute to the occurrence of end-stage renal disease. In this case, patients may need to receive renal replacement therapy [2]. E early stage of DN will be manifested as microproteinuria, which can be reversed by effective treatment. These treatments can only temporarily control the condition and have little effect on the progression of DN, and the prognosis of patients cannot be improved [5]. Studies centered on hydroxychloroquine in the treatment of patients with nephropathy have found more prominent hypolipidemic, immunomodulatory, and antiplatelet effects [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
